« Back
Home /
Ipatasertib

Ipatasertib

Item no.	HY-15186-25mg
Manufacturer	MedChem Express
CASRN	1001264-89-6
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 g 200 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category	Oncology Neuroscience Metabolism Diabetes Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Purity	99.88
Citations	[1]Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27.\|[2]Sun L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis. 2018 Sep 5;9(9):911. Biochem Pharmacol. 2020 Oct;180:114145.\|Biomaterials. 2024 Jan 1:305:122462.\|Biomed Chromatogr. 2020 Oct;34(10):e4920.\|Biomed Chromatogr. 2020 Oct;34(10):e4923.\|bioRxiv. 2024 August 18.\|bioRxiv. 2024 August 26.\|bioRxiv. 2024 Jan 16.\|bioRxiv. 2024 September 07.\|Blood. 2023 May 26;blood.2022018752.\|Cancer Immunol Immunother. 2020 Nov;69(11):2259-2273.\|Cancer Res. 2021 Mar 8;canres.3232.2020.\|Cancers (Basel). 2023 Nov 14, 15(22), 5407.\|Cell Metab. 2021 Nov 2;33(11):2247-2259.e6.\|Cold Spring Harb Mol Case Stud. 2022 Jan 10;8(1):a006140.\|Department of Laboratory Medicine, Laboratory of Hematology of the Radboudumc and Radboud Institute for Molecular Life Sciences in Nijmegen, The Netherlands.2019 Oct.\|Elife. 2020 Dec 7;9:e61405.\|EMBO Mol Med. 2025 Jan 2.\|EMBO Rep. 2020 Mar 4;21(3):e49129.\|Front Oncol. 2021 Nov 24:11:766298.\|Haematologica. 2020 Mar;105(3):661-673.\|Harvard Medical School LINCS LIBRARY\|Int J Cancer. 2021 Apr 12.\|Int J Hyperthermia. 2024 Feb 13;41(1):2310017.\|J Cell Biochem. 2024 Jun 11.\|Life Sci. 2020 Sep 1;256:117955.\|Life Sci. 2021 Apr 19;277:119520.\|Mol Cancer Ther. 2024 Jun 19.\|Mol Oncol. 2024 Jan 15.\|Nat Cell Biol. 2025 Jan 8.\|Nat Chem Biol. 2025 Feb 11.\|Nat Commun. 2024 Dec 12;15(1):10476.\|Nat Commun. 2025 Feb 25;16(1):1774.\|Oncoimmunology. 2018 Aug 6;7(10):e1488565. \|Oncol Rep. 2018 Aug;40(2):635-646. \|Oncotarget. 2016 May 17;7(20):29131-42. \|Oncotargets Ther. 2020 Aug 18;13:8197-8208.\|Oxid Med Cell Longev. 2021 Jan 12;2021:3010548.\|Patent. US20220313694A1.\|Research Square Preprint. 2024 Nov 26.\|Sci Adv. 2023 Mar 22;9(12):eadd5028.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Skelet Muscle. 2021 Mar 15;11(1):6.\|SSRN. 2023 Jun 20.\|Cell Rep. 2021 Feb 16;34(7):108744.\|Mol Cell. 2020 Sep 17;79(6):1008-1023.e4.\|Mol Cell. 2019 Jan 3;73(1):22-35.e6.
Smiles	ClC1=CC=C([C@@H](CNC(C)C)C(N2CCN(C3=C([C@H](C)C[C@H]4O)C4=NC=N3)CC2)=O)C=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GDC-0068,RG7440
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Akt; Apoptosis; Organoid
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	458.00
Product Description	Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: 3.57 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt
Isoform	Akt1; Akt2; Akt3
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15186-25mg-safety-datasheet.pdf